PharmCAT.NET

Биостатистика, фармакокинетика и клинические исследования.

  • Домашняя страница
    • О сайте
  • Материалы
    • Быстрые команды R Project
    • Ссылки
  • Инструменты
    • Рандомизационный список
  • Блог
    • Статистика
    • Phoenix WinNonlin
    • IT
    • Путевые заметки
  • Контакты
    • Контактные данные
    • Консультации
    • Конфиденциальность
  • Профиль
    • Войти
    • Зарегистрироваться

Julia:ReplicateBE – release 0.2.0

Опубликовано 26 октября, 201926 октября, 2019 frozencat

doiGitHub

Вот и подоспел релиз 0.2.0 для оценки параметров смешанной модели репликативного дизайна биоэквивалентности по методу С (EMA) – FDA model.

 

Рубрики: IT, Julia, Mixed Model, Биоэквивалентность

Навигация по записям

Предыдущая запись: ClinicalTrialUtilities: обзор
Следующая запись: Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4

Свежие записи

  • Long WS Wide: или про то, как выполнить анализ разницы изменений между группами
  • Частые вопросы: Регистрация и экспертиза по правилам ЕАЭС
  • Главные ошибки при формировании базы данных в MS Excel
  • Тест ClinicalTrialUtilities и ReplicateBE на Raspberry Pi 4
  • Julia:ReplicateBE – release 0.2.0

Галерея

20170801 173755
20180131 135949
IMG-20170806-WA0039
DJI 0072
IMG-20170802-WA0016
20170730 175202
  • Human medicines European public assessment report (EPAR): Amvuttra, vutrisiran, Date of authorisation: 15/09/2022, Revision: 5, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-12
  • Human medicines European public assessment report (EPAR): Sugammadex Piramal, sugammadex, Date of authorisation: 23/06/2023, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-12
  • Human medicines European public assessment report (EPAR): Rybrevant, amivantamab, Date of authorisation: 09/12/2021, Revision: 7, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-12
  • Human medicines European public assessment report (EPAR): Zerbaxa, ceftolozane,tazobactam, Date of authorisation: 18/09/2015, Revision: 17, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-12
  • Human medicines European public assessment report (EPAR): Nyxoid, naloxone, Date of authorisation: 09/11/2017, Revision: 10, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-12
  • Human medicines European public assessment report (EPAR): Crysvita, burosumab, Date of authorisation: 19/02/2018, Revision: 13, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2025-06-12
  • User guide of the HMA-EMA Catalogues of real-world data sources and studies
    Source: EMA - Regulatory and procedural guidelines (human and veterinary) Published on 2025-06-12
  • FDA 101: Product Recalls
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
  • OTC Monograph Drug User Fee Program (OMUFA): Understanding FY 2025 User Fees and Registration - 05/20/2025
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
  • CDER Small Business & Industry Assistance (SBIA)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
  • Untitled Letters
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
  • Anesthetic and Analgesic Drug Products Advisory Committee Roster
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
  • Oncology (Cancer)/Hematologic Malignancies Approval Notifications
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
  • FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
  • CDER Center for Clinical Trial Innovation (C3TI)
    Source: FDA - What's New: Drugs RSS Feed Published on 2025-06-11 By FDA
Предыдущие записи
Тема: Scaffold от Danny Cooper.